# FOURLIGHT-1: HCP commentary report

> 77 verified statements (47 from speakers with a confirmed clinical role) from 35 commentary sources · 7 findings · updated Oct 23, 2026

## Report

- Trial: AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)
- NCT ID: NCT06105632
- Registry: https://clinicaltrials.gov/study/NCT06105632
- Sponsor: Pfizer
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs: fulvestrant, everolimus
- Indications: Breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-23
- Last checked: 2026-10-23
- Release hash: eed3c73cb9175646795292ba28aafc521aa97e93de107f02d0b27f55c0555356

## Counts

- HCP commentary sources screened: 61
- Sources cited by verified statements: 35
- Verified statements: 77
- From speakers with a confirmed clinical role: 47
- Findings: 7
- People found in screened sources: 24
- People identity-verified: 17
- Voices cited: 13

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on FOURLIGHT-1 in the sources reviewed for this edition leads to one open question: What does benefit against these control options establish relative to the alternatives clinicians consider after CDK4/6-inhibitor progression? Its leading findings: (1) comparator adequacy is the clearest challenge to interpreting the favorable signal. (2) continued CDK targeting is seen as potentially consequential, not proof that resistance has been overcome. (3) tolerability impressions are favorable, but a comparative marrow-sparing advantage remains an interpretation. 4 more findings follow. 35 of 61 screened sources are cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What does benefit against these control options establish relative to the alternatives clinicians consider after CDK4/6-inhibitor progression?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Comparator adequacy is the clearest challenge to interpreting the favorable signal
- F2. Continued CDK targeting is seen as potentially consequential, not proof that resistance has been overcome
- F3. Tolerability impressions are favorable, but a comparative marrow-sparing advantage remains an interpretation
- F4. Patient selection and competing pathways remain open clinical questions
- F5. Positive interpretations remain qualified by the stage and completeness of the evidence
- F6. Early development commentary expressed hypotheses and patient-centered aims, not Phase 3 results
- F7. Congress interest and speculative account posts should not be mistaken for independent HCP agreement

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 8 | 9 | 6 | 6 | recorded | 3 |
| F2 | 13 | 8 | 8 | 8 | none recorded | 4 |
| F3 | 14 | 13 | 12 | 12 | none recorded | 4 |
| F4 | 10 | 6 | 5 | 6 | none recorded | 3 |
| F5 | 15 | 11 | 11 | 11 | none recorded | 3 |
| F6 | 5 | 3 | 3 | 2 | none recorded | 3 |
| F7 | 8 | 12 | 10 | 5 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 2 | 4 | 0 | 2 | 0 | 9 | 2 | 6 posts and articles | yes |
| F2 | 4 | 5 | 0 | 0 | 4 | 13 | 0 | 8 posts and articles | yes |
| F3 | 4 | 3 | 0 | 1 | 6 | 14 | 1 | 12 posts and articles | yes |
| F4 | 3 | 3 | 0 | 1 | 3 | 11 | 2 | 5 posts and articles | yes |
| F5 | 2 | 3 | 0 | 0 | 10 | 15 | 0 | 11 posts and articles | yes |
| F6 | 2 | 0 | 0 | 0 | 3 | 8 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F7 | 2 | 1 | 0 | 0 | 5 | 12 | 1 | 10 posts and articles | no |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1: F1 (4 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (10 shared claims)
- Secondary endpoints: F2 (1 shared claims), F3 (3 shared claims), F5 (6 shared claims)
- Population and setting: F1 (1 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (6 shared claims), F6 (5 shared claims)
- The comparison: F1 (7 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (7 shared claims), F6 (1 shared claims)
- Safety and tolerability: F2 (3 shared claims), F3 (13 shared claims), F5 (5 shared claims)
- Design and conduct: F2 (1 shared claims), F3 (3 shared claims), F5 (4 shared claims), F6 (4 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 77 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 35 | Counts free |
| Speaker attribution for cited voices | 13 | Paid |

## Trial aspects

10 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | discussed | 15 | 12 |
| Secondary endpoints | discussed | 6 | 5 |
| Population and setting | discussed | 15 | 13 |
| The comparison | discussed | 16 | 13 |
| Safety and tolerability | discussed | 15 | 14 |
| Design and conduct | discussed | 8 | 7 |
| Continued CDK targeting and treatment sequencing | discussed | 15 | 12 |
| CDK dependence, resistance mechanisms and biomarker-guided selection | discussed | 7 | 4 |
| Congress prioritization, brief endorsements and speculative forecasts | discussed | 8 | 10 |
| Quality-of-life ambition in second-line development | discussed | 1 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 51 | 34 |
| Bluesky threads | 9 | 0 |
| YouTube | 1 | 1 |

- Screened window: 2024-05-17 to 2026-10-23
- Cited window: 2024-05-17 to 2026-10-23
- Retrieved: 2026-10-23

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)
- Registry: NCT06105632 (https://clinicaltrials.gov/study/NCT06105632)
- Study IDs: C4391022 · 2023-506487-13-00 (CTIS (EU))
- Sponsor: Pfizer
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 333 (actual)
- Start: 2024-01-09 (actual)
- Primary completion: 2026-01-12 (actual)
- Primary endpoint: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From Initiation up to 2 years)
- Intervention: PF-07220060 CDK4 inhibitor (drug)
- Intervention: Fulvestrant (drug)
- Intervention: Everolimus (drug)
- Intervention: Exemestane (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, quoted posts and repeated announcement summaries cannot be counted as independent agreement.
- Discussion that did not name the trial or familiar aliases, or used unusual spellings, may be absent. Some identified passages were not fully assessed for clinician views.
- Clinical roles are not stated in the reviewed material for Atsushi Fushimi or Kristina Jankovic. Individual identities and HCP roles are not established for several accounts; their statements remain account-level commentary.
- No full protocol or exact-trial results publication was available in the sources reviewed. Detailed methods, subgroup findings and comparative safety interpretations therefore cannot be independently assessed here.
- No exact regulatory label for PF-07220060 was available in the reviewed material; this report does not establish an approved use.
- Earlier posts reported 264 patients and later abstract-based summaries reported 263. The sources do not explain the difference.
- Reports of 6.4% discontinuation and 4.0% treatment-related discontinuation should not be treated as interchangeable or as evidence of improvement over time.
- Historical Phase 3 descriptions are preserved as contemporaneous descriptions, not evidence of Phase 3 efficacy or an explanation of the later Phase 2 designation.
- Conditional PFS projections and indirect comparisons do not establish observed FOURLIGHT-1 medians or head-to-head rankings.
- The ESMO 2026 sources include anticipatory posts and abstract-based commentary. They do not establish the presentation date or every post's timing relative to it, so the edition cannot be characterized as entirely preceding the presentation.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-23: current edition

Last checked for new commentary 2026-10-23. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (77 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (17 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/fourlight-1-nct06105632
- Agents: POST https://www.erudio.com/api/orders with {"report": "fourlight-1-nct06105632", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=fourlight-1-06105632

## Cite

Erudio Health. FOURLIGHT-1 (NCT06105632): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 23, 2026. https://www.erudio.com/reports/fourlight-1-nct06105632

## Machine access

- JSON: https://www.erudio.com/reports/fourlight-1-nct06105632.json
- Markdown: https://www.erudio.com/reports/fourlight-1-nct06105632.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "fourlight-1-06105632"}`